• Our Professionals
  • Our Work
  • Our Insights
  • Firm
  • Careers
  • Tools
Finnegan
    • AIA Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • IP FDA Blog
    • Prosecution First Blog
  • Articles
  • IP Updates
  • Podcasts
  • Events
  • Webinars
  • Books

Article

Expert Q&A on Patent Eligibility of Life Sciences Inventions

November 14, 2019

Practical Law Intellectual Property & Technology

By Charles T. Collins-Chase; Sara A. Leiman, Ph.D.

Some experts have called the standards for determining patent eligibility under Section 101 of the Patent Act incoherent. This “incoherence” is particularly challenging for the life sciences industry where certain diagnostic inventions are now unpatentable. In this Q&A, Finnegan attorneys Charles Collins-Chase and Sara Leiman address patent subject matter eligibility, global patent strategies for protecting life sciences inventions, and other legal and regulatory mechanisms to protect life sciences inventions.

Tags

patent eligibility

Downloadable Files

  • PUBLISHED - Practical Law Intellectual Property & Technology - E

Related Practices

Patent Office Examinations

Prosecution

Related Industries

Pharmaceutical

Related Professionals

Charles_Collins-Chase
Charles T. Collins-Chase
Partner
Washington, D.C.
+1 202 408 4108
Email
Sara_Leiman
Sara A. Leiman, Ph.D.
Associate
Boston, MA
+1 617 646 1651
Email

Originally printed in Practical Law Intellectual Property & Technology on November 14, 2019. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm's clients.

Related Insights

Workshop

Life Sciences Workshop: Updates and Recent Trends in Pharmaceutical and Biotechnology Patent Law

July 18, 2019

Palo Alto

Webinar

Developing a Life Sciences Patent Portfolio

March 28, 2019

Webinar

Workshop

Life Sciences Workshop: Updates and Recent Trends in Pharmaceutical and Biotechnology Patent Law

May 2, 2019

Cambridge

Conference

CIPA Life Sciences Conference 2019

November 10-12, 2019

Brighton

Panel Discussion

Life Sciences Forum 2019

September 18, 2019

New York

Conference

Women Leaders in Life Sciences Law

July 25-26, 2019

Boston

Conference

3rd Annual Summit on Life Sciences IP Due Diligence

November 14-15, 2019

Boston

Articles

Excluded Subject-Matter the U.S. Way

June 2019

Seminar

Life Sciences Workshop: Updates and Recent Trends in Pharmaceutical and Biotechnology Patent Law

December 5, 2018

Palo Alto

Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.

We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.

A Tribute to Donald R. Dunner -
From the Partners at Finnegan

Finnegan is deeply saddened by the death of our colleague Donald R. Dunner, who passed away on October 16, 2019, after a life of dedication and inspiration to many in IP law. Don was in a category all his own with his talent and distinct knowledge of IP law. His direct approach and enthusiasm for work and life touched everyone who worked with him, and we will miss him dearly.

Finnegan
Continue to full tribute
  • Privacy
  • Disclaimer
  • EEO Statement

© 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP